10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.10), $0.04 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $150.8 million versus the consensus estimate of $146.52 million.

GUIDANCE:

10x Genomics sees FY2026 revenue of $600-625 million, versus the consensus of $612.74 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.